The Covid-19 vaccine was efficacious and safe in the Phase III trial. Credit: Prasesh Shiwakoti (Lomash) on Unsplash.

CanSino Biologics (CanSinoBIO) has reported that its recombinant Covid-19 vaccine, Convidecia, demonstrated 96% efficacy in averting severe disease in Phase III clinical trial.

The international, randomised, double-blind, multicentre and placebo-controlled trial enrolled 45,000 adult subjects aged 18 years and above in Argentina, Chile, Mexico, Pakistan and Russia.

Findings showed that one dose of the Adenovirus Type 5 Vector-based vaccine was efficacious and safe.

In addition, the vaccine was found to have 63.7% overall efficacy 14 days following inoculation in subjects, with no vaccine-associated serious side effects observed in the trial.

The trial also met all the primary efficacy goals with an overall efficacy rate of 57.5% 28 days after inoculation and an efficacy rate of 91.7% against severe disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The data met the efficacy rate needs of the World Health Organization for Covid-19 shots. Additionally, the study established the safety of Convidecia vaccine for a wide range of age groups above 18 years, including people aged over 60 years.

CanSinoBIO chairman and CEO Dr Xuefeng YU said: “This represents another milestone and provides further evidence of the strong protection provided by our single-dose vaccine, which is now approved in at least ten markets across multiple continents.

“CanSinoBIO remains committed to our mission of providing affordable, timely and mass immune protection to the global population, and will continue to collaborate with partners in the public and private sectors to improve vaccine access and have more people benefit from our technology breakthroughs.”

In another trial, a booster shot of Convidecia in previously vaccinated people offered a nearly 78-fold rise in neutralising antibody levels 14 days after inoculation.

Furthermore, homologous boosting with Convidecia six months following prime vaccination could lead to a seven-fold rise in the levels of neutralising antibodies, the company stated.

Earlier this month, the company entered a development and commercial supply partnership with Ireland-based firm Aerogen for the inhaled formulation of Convidecia.